Literature DB >> 31433616

Diastereoselective Synthesis of 3,4-Dihydropyran-3-carboxamides with in Vitro Anti-inflammatory Activity.

Li-Yan Zeng1, Baomin Xi1, Kaiqi Huang1, Jingjie Bi1, Lan Wei1, Chun Cai2, Shuwen Liu1,3.   

Abstract

A versatile and economical reaction of diketene (1), aryl amines 2, cyclic 1,3-diketones 3, primary amines 4, and aryl aldehydes 5 was explored to synthesize 3,4-dihydropyran-3-carboxamide derivatives under mild conditions. Three stereogenic centers are generated in the products, and the structure of the major diastereomer of 6{1,1,3,1} was identified by X-ray diffraction and 2D NMR spectroscopy. The scope and limitation investigation provided two series of (2S,3R,4S)-chromene-3-carboxamides in good to excellent yields with high diastereoselectivity. Two products, 6{5,3,1,1} and 6{7,3,1,1}, exhibited in vitro anti-inflammatory activity with significant inhibition of pro-inflammatory cytokine IL-6 and TNF-α expression in lipopolysaccharide (LPS)-treated Raw 264.7 cells.

Entities:  

Keywords:  2-amino-3,4-dihydropyran; anti-inflammatory; chromene-3-carboxamide; diastereoselective synthesis; five-component reaction

Mesh:

Substances:

Year:  2019        PMID: 31433616     DOI: 10.1021/acscombsci.9b00050

Source DB:  PubMed          Journal:  ACS Comb Sci        ISSN: 2156-8944            Impact factor:   3.784


  2 in total

1.  A novel substrate directed multicomponent reaction for the syntheses of tetrahydro-spiro[pyrazolo[4,3-f]quinoline]-8,5'-pyrimidines and tetrahydro-pyrazolo[4,3-f]pyrimido[4,5-b]quinolines via selective multiple C-C bond formation under metal-free conditions.

Authors:  Divyang M Patel; Hetal J Patel; José M Padrón; Hitendra M Patel
Journal:  RSC Adv       Date:  2020-05-22       Impact factor: 4.036

2.  Protective Effect of a Novel (2S, 3R, 4S)-Chromene-3-Carboxamide Derivative, Z20 Against Sepsis-Induced Organ Injury.

Authors:  Liyan Zeng; Yuhang Wang; Na Li; Mengwei Niu; Yong Wang; Peng Chen
Journal:  Inflammation       Date:  2020-08       Impact factor: 4.657

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.